We are happy to present our latest scientific contribution! Our colleagues Andrea Garcia and Bart Heeg collaborated with our partners to estimate the health impact of tafamidis in cardiomyopathy.
The publication presents a disease simulation model in Transthyretin amyloid cardiomyopathy, a rare disease with a typically poor prognosis. The model aimed to estimate the impact of tafamidis on overall survival and quality-adjusted life-years (QALY). The model incorporated New York Heart Association (NYHA) functional classifaction to model disease progression to model disease progression and estimate the impact of treatment over a patient’s lifetime.
Read the full-text publication at: https://lnkd.in/g_PRnDQ